针对癌症治疗中的小分子药物设计的最新进展:挑战和未来方向
Satya Prakash1, Priyanka Tyagi1, Pratibha Singh1
1School of Pharmaceutical Sciences, IIMT University, Meerut, India.
Current cancer drug targets
|October 30, 2024
概括
向疗法提供了一种有希望的方法来打击癌症转移,这是治疗失败的主要原因. 本综述评估了小分子抑制剂,以改善抗癌药物开发,防止转移.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 转移是抗癌治疗失败和癌症死亡率的主要驱动因素.
- 传统的化疗可以选择耐化疗细胞,促进表皮细胞转移到介质细胞 (EMT) 和远程殖民.
- 向疗法提供了比传统化疗更精确和潜在的更安全的替代方案.
研究的目的:
- 审查目前针对转移的小分子抑制剂的现状.
- 通过目标分类来评估小分子聚焦抗癌疗法的发展.
- 确定挑战,并为抗癌药物研发提出改进建议.
主要方法:
- 通过目标分类对小分子抑制剂进行广泛评估.
- 在临床试验中审查许可药物和关键候选药物.
- 对针对性抗癌药物开发当前挑战的分析.
主要成果:
- 有针对性的药物显示出有希望,可以集中在癌细胞上,同时不影响正常细胞.
- 尽管取得了进展,但对于小分子向疗法,反应率不足和耐药性等挑战仍然存在.
- 提供了针对各种转移性点的许可药物和临床候选药物的全面概述.
结论:
- 小分子抑制剂是开发有效的抗转移药物的关键领域.
- 需要进一步的研究和开发,以克服现有的障碍,并提高向抗癌疗法的疗效.
- 本综述为癌症治疗的小分子抑制剂研究提供了现有和未来的见解.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.7K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Structure-Activity Relationships and Drug Design
622
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
622
Drug Discovery: Overview
7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K
Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
